Conditions favoring long-term survival after hepatectomy for hepatocellular carcinomas.

abstract：PURPOSE:There is as yet no optimal treatment regimen for patients with epidermal growth factor receptor (EGFR) gene wild-type non-small-cell lung cancer (NSCLC) that has progressed despite cytotoxic chemotherapy. This trial was performed to evaluate the efficacy and toxicity of erlotinib, a tyrosine kinase inhibitor of...

journal_title：Cancer chemotherapy and pharmacology

authors： Kobayashi T,Koizumi T,Agatsuma T,Yasuo M,Tsushima K,Kubo K,Eda S,Kuraishi H,Koyama S,Hachiya T,Ohura N

更新日期：2012-05-01 00:00:00

abstract：:Pyrazine diazohydroxide (sodium salt, NSC 361456; PZDH) is a new antitumor drug with relatively broad activity in initial evaluations against murine leukemias, solid tumors, and two human tumor xenografts in vivo. The present studies were designed to address questions about PZDH activity on different treatment schedul...

journal_title：Cancer chemotherapy and pharmacology

authors： Harrison SD Jr,Plowman J,Dykes DJ,Waud WR,Griswold DP Jr

更新日期：1990-01-01 00:00:00

abstract：PURPOSE:6-Gingerol, a major biochemical and pharmacological active ingredient of ginger, has shown anti-inflammatory and antitumor activities against various cancers. Searching for natural products with fewer side effects for developing adjunctive therapeutic options is necessary. METHODS:The effects of 6-gingerol on ...

journal_title：Cancer chemotherapy and pharmacology

authors： Xu S,Zhang H,Liu T,Yang W,Lv W,He D,Guo P,Li L

更新日期：2020-02-01 00:00:00

abstract：PURPOSE:Some clinical studies on etoposide (Eto) have shown marked schedule dependency of the effect (starting at about 1 mg/l) and toxicity (over about 10 mg/l) whereas other studies have not confirmed these results. What are the conclusions we can draw from these inconsistent results when developing new low-dose (LD)...

journal_title：Cancer chemotherapy and pharmacology

authors： Würthwein G,Boos J

更新日期：2002-04-01 00:00:00

abstract：:This phase I study was carried out to determine the maximal tolerated dose of carboplatin (Car) together with a fixed dose of etoposide (E) and to recommend the optimal dose for a phase II study. The dose of E was 100 mg/m2 given i.v. on days 1-3, and the starting dose of Car was 200 mg/m2 given i.v. on day 1. The dos...

journal_title：Cancer chemotherapy and pharmacology

authors： Liippo K,Nikkanen V,Heinonen E

更新日期：1990-01-01 00:00:00

abstract：PURPOSE:We conducted a phase II trial to evaluate the efficacy and safety of induction chemotherapy of pemetrexed plus split-dose cisplatin followed by pemetrexed maintenance for advanced non-squamous non-small-cell lung cancer (NSCLC). METHODS:Patients with advanced or recurrent untreated non-squamous NSCLC received ...

journal_title：Cancer chemotherapy and pharmacology

authors： Koba T,Minami S,Nishijima-Futami Y,Masuhiro K,Kimura H,Futami S,Yaga M,Mori M,Kagawa H,Uenami T,Kohmo S,Otsuka T,Yamamoto S,Komuta K,Kijima T

更新日期：2018-07-01 00:00:00

abstract：:We have developed and validated a selective analytical procedure, based on ion-exchange normal-phase liquid chromatography with fluorescence detection and liquid-liquid extraction, for the analysis of vinblastine (VBL) in biological matrices. The assay is suitable for the determination of the parent compound and its m...

journal_title：Cancer chemotherapy and pharmacology

authors： van Tellingen O,Beijnen JH,Nooijen WJ,Bult A

更新日期：1993-01-01 00:00:00

abstract：PURPOSE:Carboplatin is frequently dosed to achieve a desired area under the plasma concentration-time curve (AUC) by using the Calvert or Chatelut equations to estimate carboplatin clearance. Accurate determination of glomerular filtration rate (GFR) is necessary to correctly calculate carboplatin clearance using the C...

journal_title：Cancer chemotherapy and pharmacology

authors： Donahue A,McCune JS,Faucette S,Gillenwater HH,Kowalski RJ,Socinski MA,Lindley C

更新日期：2001-05-01 00:00:00

abstract：:The pharmacokinetics of mitomycin (MMC) was studied in Wistar rats. Up to five half-lives, the plasma concentration-time curve was biphasic. The AUC changed linearly with increasing doses between 0.5 and 7.5 mg/kg, which corresponds to 0.2 and 3 times the LD50 value in rats. Most of the drug was metabolized, and only ...

journal_title：Cancer chemotherapy and pharmacology

authors： Kerpel-Fronius S,Verwey J,Stuurman M,Kanyár B,Lelieveld P,Pinedo HM

更新日期：1988-01-01 00:00:00

abstract：:Chronic myeloid leukaemia (CML) is an unusual malignancy in which myeloid progenitor cells are transformed by a single chromosomal translocation where the Bcr domain of chromosome 22 is placed adjacent to the proto-oncogene c-Abl of chromosome 9, resulting in constitutive Abl tyrosine kinase activity. This has a twofo...

journal_title：Cancer chemotherapy and pharmacology

authors： Jackson RC,Radivoyevitch T

更新日期：2014-10-01 00:00:00

abstract：PURPOSE:Angiogenesis plays a crucial role in the development, growth, and metastasis of carcinomas, and studies have reported conflicting evidence regarding the VEGFR expression in anaplastic thyroid cancer. We investigated the expression of VEGFR2 in patients with anaplastic thyroid cancer (ATC) and analyzed the clini...

journal_title：Cancer chemotherapy and pharmacology

authors： Yamazaki H,Yokose T,Hayashi H,Iwasaki H,Osanai S,Suganuma N,Nakayama H,Masudo K,Rino Y,Masuda M

更新日期：2018-10-01 00:00:00

abstract：BACKGROUND:The objective of the study was to investigate the efficacy and tolerability of weekly docetaxel in patients with platinum-refractory recurrent or metastatic squamous cell carcinoma of the head and neck (SCCHN). METHODS:Patients fulfilling the following criteria were enrolled: histologically confirmed SCCHN;...

journal_title：Cancer chemotherapy and pharmacology

authors： Cho BC,Keum KC,Shin SJ,Choi HJ,Lee YJ,Kim SH,Choi EC,Kim JH

更新日期：2009-12-01 00:00:00

abstract：:OSI-7836 (4'-thio-beta-D-arabinofuranosylcytosine) is a novel nucleoside analog in phase I clinical development for the treatment of cancer. As with other nucleoside analogs, the proposed mechanism of action involves phosphorylation to the triphosphate form followed by incorporation into cellular DNA, leading to cell ...

journal_title：Cancer chemotherapy and pharmacology

authors： Richardson F,Black C,Richardson K,Franks A,Wells E,Karimi S,Sennello G,Hart K,Meyer D,Emerson D,Brown E,LeRay J,Nilsson C,Tomkinson B,Bendele R

更新日期：2005-03-01 00:00:00

abstract：BACKGROUND:As tumors evolve, they upregulate glucose metabolism while also encountering intermittent periods of glucose deprivation. Here, we investigate mechanisms by which pancreatic cancer cells respond to therapeutic (2-deoxy-D-glucose, 2-DG) and physiologic (glucose starvation, GS) forms of glucose restriction. M...

journal_title：Cancer chemotherapy and pharmacology

authors： Philips KB,Kurtoglu M,Leung HJ,Liu H,Gao N,Lehrman MA,Murray TG,Lampidis TJ

更新日期：2014-02-01 00:00:00

abstract：PURPOSE:The effect of an anticancer treatment on tumor cell proliferation in vitro can be described as a three-dimensional surface where the inhibitory effect is related to drug concentration and treatment time. The analysis of this kind of response surface could provide critical information: for example, it could indi...

journal_title：Cancer chemotherapy and pharmacology

authors： Germani M,Magni P,De Nicolao G,Poggesi I,Marsiglio A,Ballinari D,Rocchetti M

更新日期：2003-12-01 00:00:00

abstract：:Axitinib is approved with indication in patients with advanced renal cell carcinoma (RCC). Due to the localization of this cancer, physicians sometimes have to deal with hemodialyzed patients. Data exploring hemodialysis (HD) impact on axitinib pharmacokinetic (PK) or safety are lacking. To date, no data have been pub...

journal_title：Cancer chemotherapy and pharmacology

authors： Thiery-Vuillemin A,Orillard E,Mouillet G,Calcagno F,Devillard N,Bouchet S,Royer B

更新日期：2017-06-01 00:00:00

abstract：PURPOSE:To assess the safety of the association of radiotherapy (RT) and systemic treatments for patients with metastatic malignant melanoma (mMM). METHODS:A retrospective analysis included consecutive patients treated with palliative RT, and at least one line of systemic therapy for mMM between 2001 and 2016. Treatme...

journal_title：Cancer chemotherapy and pharmacology

authors： Couty E,Vallard A,Sotton S,Ouni S,Garcia MA,Espenel S,Rancoule C,Ben Mrad M,Biron AC,Perrot JL,Langrand-Escure J,Magné N

更新日期：2019-05-01 00:00:00

abstract：PURPOSE:The purpose of this investigation was to synthesize a series of thiolo-, thiono- and dithiocarbonate and thiocarbamate derivatives of 4-demethylpenclomedine (DM-PEN), the major plasma metabolite of penclomedine (PEN) in patients observed subsequently to be an active antitumor agent and non-neurotoxic in a rat m...

journal_title：Cancer chemotherapy and pharmacology

authors： Struck RF,Waud WR

更新日期：2006-01-01 00:00:00

abstract：PURPOSE:This is a phase-I study of gefitinib in combination with temozolomide in patients with gliomas. The goal of the study was to define the maximum tolerated dose (MTD) and to characterize the pharmacokinetics of gefitinib when combined with temozolomide. PATIENTS AND METHODS:Patients were stratified according to ...

journal_title：Cancer chemotherapy and pharmacology

authors： Prados MD,Yung WK,Wen PY,Junck L,Cloughesy T,Fink K,Chang S,Robins HI,Dancey J,Kuhn J

更新日期：2008-05-01 00:00:00

abstract：PURPOSE:Tyrosine kinase inhibitors (TKI) that target MET signaling have shown promise in various types of cancer, including lung cancer. Combination strategies have been proposed and developed to increase their therapeutic index. Based on preclinical synergy between inhibition of MET and topoisomerase I, a phase I stud...

journal_title：Cancer chemotherapy and pharmacology

authors： Liu SV,Groshen SG,Kelly K,Reckamp KL,Belani C,Synold TW,Goldkorn A,Gitlitz BJ,Cristea MC,Gong IY,Semrad TJ,Xu Y,Xu T,Koczywas M,Gandara DR,Newman EM

更新日期：2018-10-01 00:00:00

abstract：OBJECTIVE:Docetaxel given orally as monotherapy results in low bioavailability of <10%. Previous studies have indicated that the intestinal efflux pump P-glycoprotein (P-gp) prevents uptake from the gut resulting in low systemic exposure to docetaxel. The purpose of this study was to determine the degree of enhancement...

journal_title：Cancer chemotherapy and pharmacology

authors： Kuppens IE,Bosch TM,van Maanen MJ,Rosing H,Fitzpatrick A,Beijnen JH,Schellens JH

更新日期：2005-01-01 00:00:00

abstract：PURPOSE:5-Fluorouracil (5-FU), an anti-cancer drug, has been used for hepatoblastoma (HB) chemotherapy in children, who may have impaired  ovarian follicle pool reserve with lasting effects to reproduction. Therefore, this study aimed to investigate 5-FU effects on survival, growth, and morphology of ovarian preantral ...

journal_title：Cancer chemotherapy and pharmacology

authors： Almeida JZ,Lima LF,Vieira LA,Maside C,Ferreira ACA,Araújo VR,Duarte ABG,Raposo RS,Báo SN,Campello CC,Oliveira LFS,da Costa TP,Abreu JG,Figueiredo JR,Oriá RB

更新日期：2021-01-20 00:00:00

abstract：PURPOSE:Trametinib is a reversible, selective inhibitor of the mitogen-activated extracellular signal-regulated kinase 1 (MEK1) and 2 (MEK2). Cardiotoxicity (congestive heart failure, decreased heart rate, left ventricular dysfunction, and hypertension) related to trametinib is an infrequent, but serious, adverse event...

journal_title：Cancer chemotherapy and pharmacology

authors： Patnaik A,Tolcher A,Papadopoulos KP,Beeram M,Rasco D,Werner TL,Bauman JW,Scheuber A,Cox DS,Patel BR,Zhou Y,Hamid M,Schramek D,Sharma S

更新日期：2016-09-01 00:00:00

abstract：:Plasmatic and salivary concentrations of 5-FU were investigated in ten patients given 5-day continuous infusions of 5-fluorouracil (5-FU) (1 g/m2/day). Measurable concentrations of salivary 5-FU were scattered ranging from 6 to 100 ng/ml. Between individual 5-FU concentrations in saliva and plasma the coefficient of c...

journal_title：Cancer chemotherapy and pharmacology

authors： Milano G,Thyss A,Santini J,Frenay M,Francois E,Schneider M,Demard F

更新日期：1989-01-01 00:00:00

abstract：:Breast cancer is presently the most predominant tumor type and the second leading cause of tumor-related deaths among women. Although advancements in diagnosis and therapeutics have momentously improved, chemoresistance remains an important challenge. Tumors oppose chemotherapeutic agents through a variety of mechanis...

journal_title：Cancer chemotherapy and pharmacology

authors： Mehraj U,Dar AH,Wani NA,Mir MA

更新日期：2021-01-09 00:00:00

abstract：:We studied the release of histamine elicited by some antineoplastic drugs in rat pleural and peritoneal mast cells. The drugs tested included the antibiotic mitomycin; the anthracyclines daunorubicin, doxorubicin, and epirubicin; the glycopeptide bleomycin; the chromopeptide dactinomycin; the platinum coordination com...

journal_title：Cancer chemotherapy and pharmacology

authors： Botana LM,Arnaez E,Vieytes MR,Alfonso A,Louzao MC

更新日期：1992-01-01 00:00:00

abstract：:Attenuation of the renal toxicity of cis-diamminedichloroplatinum (CDDP) is important in the use of this effective but cytotoxic anticancer agent. We have previously shown that the renal toxicity of CDDP can be efficiently reduced by the induction of metallothionein (MT) by preadministration of bismuth compounds in mi...

journal_title：Cancer chemotherapy and pharmacology

authors： Kondo Y,Himeno S,Satoh M,Naganuma A,Nishimura T,Imura N

更新日期：2004-01-01 00:00:00

abstract：PURPOSE:For the development of a safe and effective dual inhibitor of anticancer drug efflux transporters P-glycoprotein and multidrug resistance protein 1 (MRP1) to conquer multidrug resistance, we investigated the effects of dietary phytochemicals on the functions of P-glycoprotein and MRP1. METHODS:The effects of d...

journal_title：Cancer chemotherapy and pharmacology

authors： Nabekura T,Yamaki T,Ueno K,Kitagawa S

更新日期：2008-10-01 00:00:00

abstract：:Peripheral blood stem and progenitor cells (PBSC and PBPC), which circulate at very low levels during steady-state hematopoiesis, show a transient but marked increase during hematologic recovery from marrow-suppressive chemotherapy. To ensure rapid and sustained hematologic engraftment after autologous PBSC transplant...

journal_title：Cancer chemotherapy and pharmacology

authors： Harada M,Teshima T,Fujisaki T,Mizuno S,Miyamoto T,Takamatsu Y,Kubota A,Ohno Y,Kuroiwa M,Takenaka K,Eto T,Akashi K,Gondo H,Okamura T,Inaba S,Niho Y

更新日期：1996-01-01 00:00:00

abstract：BACKGROUND:We evaluated the influence of serum cystatin C (CysC) with respect to other glomerular filtration rate (GFR) markers on the treatment effect of everolimus in a phase II study in patients with metastatic renal cell carcinoma (mRCC). MATERIALS AND METHODS:Outcomes were from the study's primary analysis. GFR w...

journal_title：Cancer chemotherapy and pharmacology

authors： Bodnar L,Stec R,Dzierżanowska M,Synowiec A,Cierniak S,Kade G,Szczylik C

更新日期：2016-08-01 00:00:00